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Abstract  21 
Seizures are the most common neurological emergencies in the neonatal period and are 22 
associated with poor neurodevelopmental outcomes. Seizures affect up to five per 1000 term 23 
births and population based studies suggest that they occur even more frequently in premature 24 
infants. Seizures are a sign of an underlying cerebral pathology, the most common of which is 25 
hypoxic-ischemic encephalopathy in term infants. Due to a growing body of evidence that 26 
seizures exacerbate cerebral injury, effective diagnosis and treatment of neonatal seizures is of 27 
paramount importance to reduce long-term adverse outcomes. Electroencephalography is 28 
essential for the diagnosis of seizures in neonates due to their subtle clinical expression, non-29 
specific neurological presentation and a high frequency of electro-clinical uncoupling in the 30 
neonatal period. Hypoxic-ischaemic encephalopathy may require neuroprotective therapeutic 31 
hypothermia, accompanying sedation with opioids, anticonvulsant drugs or a combination of 32 
all of these. The efficacy, safety, tolerability and pharmacokinetics of seven anticonvulsant 33 
drugs (phenobarbital, phenytoin, levetiracetam, lidocaine, midazolam, topiramate and 34 
bumetanide) are reviewed. This review is focused only on studies reporting electrographically 35 
confirmed seizures and highlights the knowledge gaps that exist in optimal treatment regimens 36 
for neonatal seizures. Randomised controlled trials are needed to establish a safe and effective 37 
treatment protocol for neonatal seizures.  38 
Key points: 39 
• The optimal treatment protocol for neonatal seizures remains elusive. Phenobarbital 40 
remains the first-line antiepileptic of choice, despite suboptimal efficacy and altered 41 
pharmacodynamic effects in neonates. There is currently no consensus regarding 42 
second-line drug choice, which often varies between phenytoin, lidocaine, 43 
levetiracetam or benzodiazepines.  44 
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• Hypothermia is the current standard of care for neuroprotection in HIE and many novel 45 
neuroprotective drugs are also emerging. Drug-drug interactions as well as drug-46 
hypothermia interactions between antiepileptic drugs, novel neuroprotectants and 47 
hypothermia need to be investigated prior to administration in neonates, due to the 48 
potential for both pharmacokinetic and pharmacodynamic interactions.  49 
• Continuous EEG monitoring is essential as a measure of antiepileptic efficacy. 50 
• Randomised, controlled trials are required to establish a safe and effective treatment 51 
regimen for neonatal seizures. 52 
1. Neonatal seizures-an overview 53 
Neonatal seizures affect between one and five full-term neonates per 1000 live births, and are 54 
the most common neonatal neurological emergencies [1]. Moreover, the incidence of seizures 55 
increases in very low birth weight infants [2]. Phenobarbital remains the first line drug for 56 
treatment of neonatal seizures, despite having only around 50% efficacy [3]. There is little 57 
consensus about the best second-line treatment for neonatal seizures and there is considerable 58 
off-label use of antiepileptic medications with sparse efficacy data in the neonatal period.  59 
 1.1 Aetiology of neonatal seizures 60 
Seizures are a hallmark of neurological injury and approximately 60% of all neonatal seizures 61 
are attributable to hypoxic-ischaemic encephalopathy (HIE) [4]. In Europe, HIE is the third 62 
most common cause of neonatal mortality, accounting for 9% of all deaths and 21% of term 63 
deaths, while globally it is estimated to cause approximately one million neonatal deaths each 64 
year [5, 6]. For the survivors of HIE, there is significant secondary morbidity, including 65 
cerebral palsy (29%), cognitive delay (45%), seizure disorders (12%), sensorineural deafness 66 
(9%), and visual loss (26%) [7]. Seizures in HIE may exacerbate the underlying cerebral injury 67 
and increase the risk of detrimental neurodevelopmental consequences [8-11]. Perinatal arterial 68 
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ischaemic stroke is the second most common cause of seizures in term neonates and accounts 69 
for 7.5%-20% of neonatal seizures [12, 13]. Seizures also arise from intracranial haemorrhage 70 
(7%-18%), congenital cerebral malformations (3%-17%), infection (2%-14%), metabolic 71 
causes (3%-5%), electrolyte imbalances (1%-4%) and other less common causes [14, 15]. 72 
There is little evidence on which to base recommendations for antiepileptic protocols 73 
regardless of seizure aetiology, although a prudent approach would be to treat the underlying 74 
cause and administer antiepileptic treatment according to hospital protocols. 75 
 1.2 Pathophysiological aspects of neonatal seizures 76 
Seizures are the result of excessive electrical firing of neurons in the brain [16]. The immature 77 
brain is more susceptible to seizures, primed by the early development of excitatory 78 
neurotransmitters, delayed inhibitory function of gamma-amino butyric acid (GABA) and an 79 
excess of excitatory glutamatergic neurons which are composed of more excitable subunits 80 
than the equivalent in adults [17, 18].  81 
The binding of GABA agonists/modulators to the GABAA receptor triggers either an influx or 82 
an efflux of chloride ions, depending on the neuronal equilibrium potential for chloride [19]. It 83 
has been shown that the expression of inward sodium-potassium-chloride cotransporter 84 
(NKCC1) in human cortex is increased at birth compared to one year of age, whereas 85 
expression of outward potassium-chloride cotransporter (KCC2) increases from birth onwards 86 
[17]. This leads to an accumulation of intracellular chloride in immature neurons through 87 
NKCC1, thus the equilibrium potential for chloride becomes positive in relation to the resting 88 
membrane potential [19]. In immature neurons, activation of the GABAA receptor results in 89 
chloride efflux and neuronal depolarisation [19]. Furthermore, birth injuries such as ischaemia 90 
increases NKCC1 and decrease KCC2 expression, whereas hypoxic-ischaemic injury increases 91 
NKCC1 alone [20]. For these reasons, treatment of neonatal seizures with GABAA agonists, 92 
such as phenobarbital or benzodiazepines, may be suboptimal. Moreover, GABAA receptors 93 
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are expressed at low levels in human and rodent cortex and contain less α1 subunits than their 94 
adult counterparts, decreasing their sensitivity to modulation by benzodiazepines [21]. Female 95 
rats have increased levels of outward potassium-chloride transporter (KCC2), which translates 96 
to an inhibitory GABA action emerging earlier in females than in males [22]. Indeed, sex 97 
differences have been noted in mice, rats and humans with regards to susceptibility to brain 98 
injury, mechanisms of brain injury and response to treatment [23]. The increased seizure 99 
susceptibility due to developmental peculiarities of immature brain and excitatory GABA 100 
function might suggest that a class of antiepileptic drug (AED) other than GABA modulators 101 
should be considered as a first-line treatment for neonatal seizures. Furthermore, the sex 102 
differences observed in cotransporter expression raise questions regarding a differential 103 
approach to seizure treatment in male and female subjects.  104 
 1.3 Diagnosis of neonatal seizures 105 
The diagnosis of neonatal seizures is challenging. Clinical seizure detection may lead to both 106 
over- and under-diagnosis [24]. Apart from classical tonic, clonic and myoclonic seizures, 107 
neonates may exhibit a wide variety of subtle seizure presentations including eye deviations, 108 
blinking, staring, chewing, sucking, cycling and boxing limb movements, apnoea and blood 109 
pressure changes [25]. Only a small portion of suspected neonatal clinical seizures are 110 
confirmed by electroencephalography (EEG) [24], while clinical signs may be absent in up to 111 
80-90% of electrographic seizures [26, 27]. The only randomised controlled trial comparing 112 
the effect of treatment of  electrographic-only seizures to clinical-only seizures in neonates 113 
with HIE using a traditional AED protocol (phenobarbital up to 40 mg/kg, followed by 114 
fosphenytoin 20 mg/kg and third line midazolam bolus or infusion) demonstrated significantly 115 
reduced seizure burden in neonates treated based on electrographic seizure activity [28].  116 
The absence or cessation of clinical correlates when electrographic seizures are confirmed is 117 
called electro-clinical uncoupling [29, 30]. The subtle clinical seizure presentation in neonates 118 
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and the phenomenon of electro-clinical uncoupling may be at least partly explained by the 119 
incomplete axonal dendritic and synaptic development, as well as incomplete myelination in 120 
the immature brain. Synaptic connectivity continues to increase until 2 years of age [31, 32]. 121 
Clinical seizures can become even more difficult to detect following the administration of 122 
anticonvulsants or sedative agents, during hypothermia treatment or in neonates in critical 123 
condition [30, 33]. Both phenobarbital and phenytoin produced equal rates of uncoupling, with 124 
58% of neonates exhibiting only or mostly electrographic evidence of seizures after drug 125 
administration [30]. Differential maturation of transporters that control intracellular chloride 126 
levels in different regions of the brain could be the mechanism underlying AED-induced 127 
uncoupling. Phenobarbital, a GABAA agonist, reduced epileptiform power in slices taken from 128 
the ventroposterior thalamus of postnatal day 9/10 rat pups, but had no such effect on slices of 129 
neocortex from the same animals, suggesting that GABA signalling is inhibitory in the 130 
ventroposterior thalamus, but may be excitatory in the neocortex at this age [29].  131 
A simplified and compressed version of multichannel EEG called amplitude-integrated EEG 132 
(aEEG) uses fewer channels than traditional EEG and requires less expertise for interpretation. 133 
It is often used for diagnosis of neonatal seizures in the neonatal intensive care unit (NICU) 134 
[1]. However, some seizures may be missed using this technology, as it struggles to identify 135 
low amplitude, short duration (< 1 minute) and infrequent seizures [27, 34, 35]. In addition, 136 
neonatal seizures often remain focal and do not generalise [27]. Therefore, focal seizures in the 137 
regions beyond aEEG electrode placement sites may remain undetected. Furthermore, artefacts 138 
that mimic seizure activity on aEEG may cause additional complications and lead to false 139 
positive readings [36].  Experience is required for reliable interpretation of both clinical and 140 
electrographic seizures, and studies have shown that non-expert users perform poorly in aEEG 141 
seizure detection [37]. There has been considerable effort in recent years to develop an 142 
automated neonatal seizure detection system to aid in clinical decision support in the NICU 143 
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and one such algorithm is currently undergoing a clinical trial across Europe (NCT02160171) 144 
[38, 39].  145 
Reliable diagnosis of neonatal seizures can only be performed using continuous EEG (cEEG) 146 
monitoring which is considered the gold standard for the diagnosis of all neonatal seizures and 147 
for the assessment of anticonvulsant efficacy [24]. The role of cEEG monitoring extends to the 148 
differential diagnosis of seizure aetiology, particularly for HIE, stroke, infantile 149 
encephalopathy and congenital metabolic diseases [40, 41]. Multichannel cEEG monitoring of 150 
neonates at risk of seizures or suspected clinical seizures should be implemented rapidly to 151 
confirm diagnosis and optimise outcomes [42]. Laboratory tests and magnetic resonance 152 
imaging are also required to determine the underlying seizure pathology [43]. A protocol for 153 
laboratory workup in seizures is detailed in a previously published review [25].  154 
  155 
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2. Treatment strategies  156 
Once neonatal seizures are suspected, the neonate should be rapidly assessed for treatable 157 
underlying causes, such as hypoglycaemia or electrolyte disturbances [44]. AEDs are then 158 
administered according to clinical preference, independent of seizure cause. AEDs should only 159 
be initiated once seizure activity is confirmed, due to a lack of evidence for any positive 160 
outcomes if they are administered in the absence of seizures [3, 45]. 161 
As HIE is responsible for the majority of neonatal seizures and seizures are treated with the 162 
same AEDs regardless of underlying injury, the various treatments available for HIE-induced 163 
seizures are reviewed here. Neuro-protective strategies, currently led by therapeutic 164 
hypothermia, are initiated during the latent phase of HIE and may interact with AEDs that are 165 
administered during the secondary phase of HIE, and are therefore briefly mentioned in this 166 
context (Section 3). 167 
2.1 Drug treatment for neonatal seizures 168 
Neonatal seizures are neurological emergencies and must be treated promptly since seizures, 169 
particularly high seizure burden, may exacerbate neuronal injury in the immature brain and 170 
contribute to pathogenesis of later cerebral palsy and epilepsy [10, 46, 47]. In neonates with 171 
HIE who do not receive therapeutic hypothermia, there is a peak in seizure burden shortly after 172 
seizure onset (within six hours) [48]. AEDs should ideally be administered within the time 173 
period prior to the peak seizure burden. However, current AEDs are sub-optimal in terms of 174 
effectiveness, safety and long-term outcomes [3, 49] and a systematic review has shown that 175 
the use of AEDs following perinatal asphyxia in the absence of confirmed seizures are of little 176 
benefit with no improvement in survival or neurodevelopmental outcome [45]. AEDs used in 177 
neonates act through a variety of mechanisms to reduce excitability in the brain, thereby 178 
suppressing the seizure. The mode of action of neonatal AEDs is illustrated in Fig. 1. 179 
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Insert Figure 1 here 180 
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2.2 Antiepileptic Drugs: Efficacy, Safety and Tolerability 182 
The most frequently used AEDs in both term and preterm babies include phenobarbital, 183 
phenytoin, midazolam, lorazepam, clonazepam, and lidocaine [54]. Current recommendations 184 
suggest initiating anticonvulsant therapies in neonates with phenobarbital, adding either a 185 
benzodiazepine, phenytoin or lidocaine as a second-line agent if seizures continue [3] (Table 186 
1). In a treatment protocol designed by Slaughter et al., a similar treatment regimen is proposed 187 
starting with phenobarbital, followed by levetiracetam, phenytoin or lidocaine, and finally the 188 
addition of a benzodiazepine as a third-line agent [55]. In other studies, if seizures were not 189 
controlled by phenobarbital and/or phenytoin, drugs such as midazolam, clonazepam, 190 
lidocaine, levetiracetam and topiramate have been used [42, 55-57]. A survey of clinicians in 191 
USA found that a majority (73%) would use levetiracetam and/or topiramate despite limited 192 
knowledge about the pharmacokinetics of these drugs in newborn infants [58]. However, 193 
topiramate was shown to exacerbate cell apoptosis caused by phenytoin in rat pups, despite the 194 
absence of neurodegenerative properties when administered as monotherapy [59]. Thus, certain 195 
AED combinations may be detrimental to neurodevelopment. While the use of other AEDs 196 
(carbamazepine, paraldehyde, sodium valproate, vigabatrin, lamotrigine) in the treatment of 197 
neonatal seizures has been described in case reports [60, 61] and recent animal studies have 198 
shown a beneficial anti-seizure effect of potassium channel opener flupirtine in a hypoxia-199 
model of neonatal seizures [62], we will focus on AEDs that have been recommended in 200 
neonatal treatment protocols and that have been studied in conjunction with EEG monitoring. 201 
AED efficacy is defined differently in many of the studies cited in Sections 2.2, 2.3 and Table 202 
1, but the vast majority state that efficacy is an 80% reduction in seizure severity or complete 203 
seizure cessation, with one notable exception that defined 50% seizure reduction as efficacious 204 
[33]. However, further work is required to define AED efficacy optimally using EEG criteria 205 
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in view of the well described natural evolution of acute seizures in neonates, particularly those 206 
with HIE [48, 63, 64].  207 
  2.2.1 Phenobarbital and phenytoin 208 
Phenobarbital remains the first choice of AED in neonatal seizures, due to an extensive history 209 
of its use in this population [3]. Phenobarbital acts by increasing GABAA mediated inhibition 210 
[51]. Neonates with persistent seizures are likely to have more severe brain damage and poor 211 
neurodevelopmental outcomes; thus half of the babies on two AEDs and a staggering 95% of 212 
babies on three AEDs were reported to have poor outcomes [47, 65]. Phenytoin, an antiepileptic 213 
that reduces excitatory neurotransmission by blocking a voltage-gated sodium channel, is often 214 
administered second-line to phenobarbital [51]. A Cochrane review found that there was very 215 
little supportive evidence for the main AEDs currently used in the neonatal period, as even 216 
with a combination treatment with phenobarbital and phenytoin, seizures remained in up to 217 
50% of babies, as confirmed by cEEG [42, 49, 66, 67].  218 
  2.2.2 Lidocaine 219 
Lidocaine acts by inhibiting voltage-gated sodium channels, thereby preventing depolarisation 220 
[50]. Lidocaine is a promising AED in neonatal seizures administered either second-line or 221 
third line with efficacy rates as high as 78%, based on aEEG assessment [68-70]. A very recent 222 
retrospective study of aEEG data has found that lidocaine as a second- or third-line AED had 223 
a good (seizure control for at least four hours) or intermediate (seizure control for at least two 224 
hours) antiepileptic effect in 71.4% of neonates, both term and preterm [70]. An earlier study 225 
demonstrated the lower efficacy rate of 60% with lidocaine, supported by cEEG [42]. One of 226 
the main challenges of using lidocaine in neonates is the risk of adverse events, particularly 227 
with plasma concentrations >9mg/L, including both bradycardia and ventricular tachycardia 228 
[68, 71]. As with many AEDs, a tailored neonatal dosage regimen is needed, as cardio-toxic 229 
levels were found in the majority of neonates treated with a standard lidocaine infusion [68]. 230 
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A neonate-specific regimen was designed using pharmacokinetic modelling, and optimal 231 
lidocaine plasma levels were achieved in the majority of treated full-term neonates [68]. 232 
Furthermore, lidocaine dosing was studied in both term and preterm neonates, and it was found 233 
that both cohorts of neonates should receive approximately 50% of the previously 234 
recommended dose i.e. a 1 kg neonate should receive 52mg as opposed to 110mg [72]. 235 
However, lidocaine demonstrated a good safety profile in neonates [73].  236 
  2.2.3 Benzodiazepines 237 
Benzodiazepines have had varied success as second- and third-line agents in the treatment of 238 
neonatal seizures. Benzodiazepines allosterically modulate the chloride channel in the GABAA 239 
receptor to increase inhibitory neurotransmission [51]. Midazolam response rates vary from 0-240 
100%, with both 0% and 100% efficacy being observed using cEEG monitoring (see Table 1) 241 
[42, 67]. Efficacy rates measured by aEEG are reported as 50% when midazolam is used as a 242 
second-line AED, increasing to 73-100% when administered as a third-line AED [69, 74]. 243 
Midazolam appears to be less effective than lidocaine at treating persistent seizures, 244 
particularly those caused by the most severe form of HIE [69, 75]. 245 
The evidence for the effect of other benzodiazepines used in neonatal seizures is less 246 
convincing [55]. Clonazepam did not abolish any seizures as a second-line AED in three 247 
neonates monitored by cEEG [42]. The support for lorazepam as an AED is sparse, with less 248 
than half of the studied neonates monitored by cEEG [76, 77]. Seizure control rates were as 249 
high as 86% and 100% in two studies, but these results are unreliable due to the absence of 250 
cEEG monitoring [76, 77]. 251 
  2.2.4 Levetiracetam 252 
Levetiracetam is a relatively new AED which is proposed to act through synaptic vesicle 253 
glycoprotein 2A (SV2A) which is a protein thought to be involved in the release of 254 
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neurotransmitters [78]. Levetiracetam is efficacious in treating various seizures in both adults 255 
and children. In addition, levetiracetam has a very favourable pharmacokinetic and safety 256 
profile in neonates [79, 80]. Levetiracetam has demonstrated some efficacy as a neonatal and 257 
paediatric AED, according to cEEG findings which show 35-64% efficacy within 24 hours, 258 
rising to improvements in 52-100% of patients in 72 hours [33, 56]. Levetiracetam was initiated 259 
as a second- or third- line AED in the majority of recorded cases [33]. Evidence from 260 
randomised-controlled trials is needed to endorse levetiracetam as a safe and effective AED. A 261 
trial is ongoing in America looking at the safety, efficacy and pharmacokinetic profile of 262 
levetiracetam in neonates (NCT01720667), with more efficacy/safety trials planned in France 263 
(NCT02229123) and China (NCT02550028) [38].  264 
  2.2.5 Topiramate 265 
Topiramate reduces the frequency of action potential firing by altering GABA 266 
neurotransmission, blocking voltage-gated sodium channels and by weakly blocking AMPA 267 
glutamate receptors [81]. Similar to levetiracetam, pharmacokinetic and safety profiles are 268 
favourable, but little is known about the safety, efficacy or pharmacokinetics in a critically-ill 269 
newborn population [57]. In a small, retrospective study, topiramate was considered an 270 
effective add-on agent in neonatal seizures in four out of six neonates, and no major safety 271 
concerns were highlighted [57]. However, this study was limited by the lack of EEG 272 
monitoring [57].  273 
2.3 Potential adjunct antiepileptics 274 
2.3.1 Bumetanide 275 
Bumetanide is a potential adjunct to AED treatments for neonatal seizures [82]. A number of 276 
years ago, bumetanide was observed to have antiepileptic effects in kainic acid-induced 277 
seizures in vivo [83]. This was believed to be due to its ability to block ion cotransporters in 278 
neurons and glia of the central nervous system, which in turn affected GABA signalling [83]. 279 
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Bumetanide blocks NKCC co-transporters, NKCC1 and NKCC2, which both move chloride 280 
into cells [84]. Bumetanide was originally developed as a loop diuretic, which reduces oedema 281 
by inhibiting the reabsorption of sodium, potassium and chloride through NKCC2 in the thick 282 
ascending loop of Henle of the kidney [84]. Bumetanide also inhibits NKCC1, an isoform of 283 
the NKCC cotransporter that is widely expressed, including on neurons in the brain [84]. 284 
GABA is excitatory in immature neurons due to the accumulation of chloride through NKCC1 285 
[85]. By preventing intracellular chloride build-up, bumetanide is thought to decrease or even 286 
reverse the excitatory action of GABA, thus presenting a potentially useful combination 287 
therapy with GABAergic anticonvulsants [64, 82]. There are gaps in our knowledge of this 288 
potential adjunct to AEDs for the treatment of neonatal seizures, namely the dose at which it 289 
acts in the brain, the human blood-brain barrier permeability/transport of bumetanide as well 290 
as its effect on development of the central nervous system (CNS). Two clinical trials were 291 
initiated to establish the safety and efficacy of bumetanide in neonatal seizures, one in Europe 292 
(NCT01434225) and one in the USA (NCT00830531) [38]. In the European dose-finding 293 
clinical study, bumetanide was administered according to a bivariate Bayesian sequential dose-294 
escalation design, in which participants were treated with four doses of bumetanide 295 
(0.05mg/kg-0.3mg/kg) each given twelve hours apart, with the first dose given in conjunction 296 
with phenobarbital [64]. However, the trial was concluded early as the benefit: risk ratio was 297 
no longer favourable and the efficacy endpoint was not achieved in any of the trial participants 298 
[64, 86]. It has been suggested that this is partially due to a poor CNS effect of bumetanide at 299 
the doses used and evidence to corroborate this have come from animal studies that indicate a 300 
poor brain permeability of bumetanide [87]. Many studies are examining novel ways to 301 
enhance brain levels of bumetanide in an effort to overcome the pharmacokinetic issues 302 
hindering its therapeutic success [87-90]. 303 
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Table 1: Drug treatments of neonatal seizures-efficacy, safety and tolerability 304 
Drug Place in 
treatment 
protocol 
Efficacy Safety Tolerability 
Phenobarbital First-line. Effective in 43% of neonates 
in a randomised controlled 
trial (n = 30) [66].  
Phenobarbital achieved 
seizure control in 50% of 
neonates (n = 22) [42], and 
47% of neonates in a further 
study (n = 32) [67].  
Cost-effective AED [91]. 
May impair 
neurodevelopment and 
increase apoptosis of 
neurons [92]. 
Potential for drug-drug 
interactions. 
Many CNS side-
effects i.e. sedation, 
impaired cognition, 
depressed mood [91]. 
Phenytoin Second-line. Response in 45% of neonates 
to a dose that achieves a free 
plasma concentration of 
3µg/mL (n = 29) [66].  
Concerns about 
potential detrimental 
effect on developing 
neurons [60]. 
Potential for drug-drug 
interactions [55]. 
No changes in cardiac 
or respiratory 
function observed 
[66] 
Levetiracetam Emerging. 
Second- or 
third-line [3, 
55]. 
Effect may be 
additive with 
other AEDs 
[93]. 
Effective with twice daily 
dosing. 
Efficacious in 82% of 
preterm neonates with 
seizures (n=11) [94]. 
Achieves full control of 
seizures in 33% (n = 18) [95], 
35% (n = 23) [33] and 
between 32% and 100% of 
cases, depending on the 
treatment duration (n = 22) 
[56]. 
Does not cause 
neuronal apoptosis in 
rat pups [93]. 
Side effects in infants 
and children: 
somnolence and 
irritability. 
 
Well tolerated [79]. 
Lidocaine Second- or 
third-line. 
Response rate varies from 
60% (n = 5) [42], to 71.4% (n 
= 413) [70], to 76% (n = 20) 
[68] and 77% (n = 22) [69]. 
Optimised dosing regimen 
achieved seizure control in 
78% neonates ( n = 15) [68]. 
Cardiac toxicity i.e. 
bradycardia-increased 
risk following other 
cardio-toxic agents e.g. 
phenytoin.  
Risk of arrhythmias in 
5% patients [68]. 
 
Midazolam Second-line. 
 
Reported response to 
treatment shows a wide 
variability from no response 
(n = 3) [42] to 50% (n = 8) 
[69] to 73% (n = 15) [74] to 
100% response (n = 13) [67]. 
Improved neurodevelopment 
at 1 year of age compared to 
non-responders [67]. 
Higher doses or 
combination treatment 
with hypothermia may 
cause cardiac 
depression [69, 75]. 
Short-term drowsiness 
observed [67]. 
Well tolerated, no 
serious adverse 
effects noted [67]. 
Topiramate Emerging. Efficacy studies in neonates 
ongoing [81]. Efficacy of 
67% in one small, 
retrospective study (n = 6), 
but no EEG monitoring so 
unreliable [57].  
Hypothesised to have 
synergistic neuro-protective 
effects in neonates; reduces 
brain injury in animal models 
of HIE [96]. 
Seems safe- no increase 
in risk of death, short-
term detrimental effects 
or gross brain 
pathology [97]. 
Well-tolerated, no 
adverse effects noted 
[96] 
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Bumetanide Emerging. Low efficacy rates of ~36% 
(n = 14) with research 
protocol doses of between 
0.05 mg/kg and 0.3 mg/kg 
given 12 hours apart for a 
total of four doses-rescue 
AEDs were required by most 
neonates and efficacy 
endpoint not met by any trial 
participants [64, 86]. 
Potential risk of 
ototoxicity, especially 
if given concomitantly 
with other ototoxic 
drugs [64]. Other side 
effects include 
dehydration. 
Well tolerated up to 
0.1mg/kg dose [64]. 
 305 
2.4 Pharmacokinetic properties of AEDs  306 
There are a variety of physiological differences between neonates and adults. These variations 307 
in physiology affect all pharmacokinetic processes in the neonate, including absorption, 308 
distribution, metabolism and elimination [60]. These variations are detailed in a review by 309 
Alcorn et al., but the salient changes are noted in Table 2. Key pharmacokinetic parameters, 310 
including volume of distribution (Vd), fraction unbound in plasma (fu), clearance (Cl) and 311 
elimination half-life (t1/2), are different in neonates compared to adults. Moreover, there is wide 312 
variability in these pharmacokinetic parameters within the neonatal population, as can be seen 313 
by the ranges reported (Table 3). 314 
  315 
17 
 
Table 2: Physiological differences between neonates and adults 316 
 317 
 318 
Stage Pharmacokinetic parameter Neonate Adult 
Absorption Gastric pH 6-8 2 
Gastric emptying time Reduced rate - 
Intestinal Motility Reduced rate - 
Distribution Body composition 
 Water 
 Fat 
 
74% 
14% 
 
55-60% 
~20% 
Plasma proteins 
 Albumin 
 α1 acid glycoprotein 
 
~75% 
~25% 
 
100% 
100% 
Metabolism Enzyme expression 
 Foetal 
o ST, GST 
 Early Neonatal 
o UGT, NAT 
 
 
0-10% 
 
25-37.5% 
 
 
100% 
 
100% 
 
Cytochrome P activity 
 Foetal 
o 3A7 
 Early neonatal 
o 2D6 
o 2E1 
 Neonatal 
o 1A2 
o 2C 
o 3A4 
 
 
500-600% 
 
4-24% 
21-36% 
 
5-20% 
2-42% 
3-29% 
 
 
100% 
 
100% 
100% 
 
100% 
100% 
100% 
Bacterial flora Very limited 100% 
Excretion Glomerular filtration rate ~90% 100% 
Tubular secretion ~50% 100% 
Renal bloodflow ~65% 100% 
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 319 
Table 3: Drug treatments of neonatal seizures from published studies-pharmacokinetics 320 
AED Dose t1/2 
(h) 
fu 
(%) 
Cl 
(L/hr/kg) 
Vd 
(L/kg) 
Ref 
Phenobarbital DL: 20mg/kg (twice if 
required) 
DM: 5mg/kg/day  
73.9-154.5  57-64  0.0053-0.0141  0.64-1.17  [55, 66, 99-102] 
Phenytoin DL: 20mg/kg 
DM: 5mg/kg/day  
Wk 1: 20.7 ± 
11.6 
Wks 2-4: 
7.6 ± 3.5 
19.8 ± 2.6  0.00151-0.139  
 
0.8 ± 0.26 
 
[55, 103, 104] 
Levetiracetam DL: 10-50 mg/kg 
DM: 10-80 mg/kg/day (mean 45 
mg/kg/day) 
Day 1: 18.5 ±7.1 
Day 7: 9 ± 2 
~100  0.042-0.078  0.89-1.01  [33, 55, 56, 79, 
95] 
Lidocaine DL: 2mg/kg 
DM (normothermia): 5-7 
mg/kg/h for 4 h, 2.5-3.5 
mg/kg/h for 6-12 h, 1.25-1.75 
mg/kg/h for 12 h 
*Altered DM recommended in 
hypothermia-see ref. 54 
5.2-5.4 20-40 0.462-1.68 3-3.2 [54, 60, 68, 72] 
Midazolam DL: 0.05-0.15mg/kg 
DM: 0.06-0.4 mg/kg/h 
6.9 3.1 0.124 1-1.7 [55, 105] 
Topiramate DM: 5mg/kg-10mg/kg daily 35.6 ± 19.3 ~85 0.0156 ± 0.0048 0.6-1 [60, 81, 96, 102] 
a t1/2: half-life; fu: fraction unbound; Cl: clearance; Vd; volume of distribution; DL: Loading dose; DM: Maintenance dose; Wk: week.321 
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 322 
3. Combining therapeutic strategies 323 
3.1 Adjunct therapies in HIE with potential for interaction with antiepileptics 324 
3.1.1 Hypothermia 325 
Hypothermia has demonstrated neuro-protective properties in neonates with moderate to severe 326 
HIE [107-109]. Since the introduction of therapeutic hypothermia, the composite risk of death 327 
and major disability has been reduced by approximately 25% [108]. Neurological outcomes in 328 
cooled neonates with HIE improved at both 18 months and six-seven years of age [108, 109]. 329 
Hypothermia significantly reduces seizure burden, as measured by cEEG, in neonates with HIE 330 
[110, 111]. Seizure burden during hypothermia is characterised by a more even distribution 331 
over time (as opposed to the accumulation seen at seizure-onset in normothermia) and de-novo 332 
seizures may occur after re-warming [10, 48, 63]. It has been proposed that hypothermia should 333 
also be tested as a therapeutic strategy in late premature neonates with HIE and neonatal stroke, 334 
both of which can also result in seizures [112].  335 
3.1.2 Emerging neuro-protective treatments 336 
Additional neuro-protective strategies that are emerging include xenon, erythropoietin, 337 
melatonin, allopurinol and sevoflurane [113-119]. Thus far, the authors have found no reports 338 
of combination treatment with AEDs and emerging neuro-protective drugs. However, the 339 
combination of these novel neuro-protective agents, hypothermia and AEDs are a definite 340 
possibility in the future. Briefly, xenon protects the brain from excitatory injury by 341 
antagonising the N-methyl-D-aspartate (NMDA) glutamate receptor reducing total 342 
neurotransmission and is currently under investigation in a Phase 2 trial [120]. Erythropoietin 343 
has anti-inflammatory properties and is also anti-apoptotic [121, 122]. It has been shown to 344 
reduce detrimental neurodevelopmental outcomes in neonates with moderate-severe HIE 345 
[123]. Melatonin reduces oxidative stress through a variety of mechanisms, such as scavenging 346 
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oxygen free radicals and has been shown to augment neuroprotection by hypothermia in a 347 
piglet model of HIE [117]. Sevoflurane reduced hippocampal apoptosis in a rat model of 348 
intrauterine perinatal asphyxia and thus may be neuroprotective [113]. Allopurinol was found 349 
to have anti-oxidant properties [116].  350 
3.1.3 Sedation 351 
Intravenous morphine is commonly used as a sedative during hypothermia, as it reduces pain 352 
and stress, allows the patient to tolerate hypothermia and can be titrated to optimal response 353 
[124]. In a preclinical model of HIE, hypothermia without sedation lacked neuro-protective 354 
properties [125]. In a small group of term and preterm neonates without underlying brain 355 
injury, morphine infusion at a rate of 10-20 mcg/kg/hour was found to be associated with 356 
excessive epileptiform activity on cEEG [126].  357 
It is known that morphine clearance is decreased during hypothermia, resulting in an increased 358 
concentration of morphine in both cerebrospinal fluid and plasma [127, 128]. In terms of 359 
pharmacodynamic considerations, the affinity of morphine for its receptor appears reduced in 360 
hypothermia, but the incidence of hypotension is increased [127, 129]. Neonates with HIE who 361 
are sedated with opioids show less brain injury and display better outcomes [130]. Little is 362 
known about drug-drug interactions with AEDs, but it is advised that barbiturates such as 363 
phenobarbital may increase the sedating effect of opioids [131]. 364 
3.2 Antiepileptics and hypothermia 365 
It is thought that synergistic therapy including a traditional AED and hypothermia may 366 
augment neuro-protective properties of either treatment given alone [132]. Combination 367 
treatments need to be explored further to complement this claim. However, caution needs to be 368 
exercised as hypothermia may alter pharmacokinetics of AEDs in neonates by decreasing 369 
absorption, distribution or metabolism/clearance [100, 133-135]. Moreover, as multi-organ 370 
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dysfunction is frequently a characteristic of HIE, the combination of therapeutic hypothermia 371 
and organ impairment, particularly renal and hepatic, may have additive detrimental effects on 372 
fundamental pharmacokinetic processes [136]. The rewarming phase following hypothermia is 373 
another period of pharmacokinetic and pharmacodynamic uncertainty and is likely to be a 374 
window of time in which serious toxicity and adverse reactions could occur, due to a lag time 375 
between the return of normal metabolic enzyme and transporter function [135]. There have 376 
been reports of seizures re-occurring during the rewarming phase, but the affected infants were 377 
not receiving regular AEDs [10, 137]. Thus, combination treatment with hypothermia and 378 
AEDs may be useful, but must be approached with caution due to uncertainties regarding the 379 
effect of hypothermia on efficacy, safety and pharmacokinetics of such medications. It is 380 
important to identify AEDs, doses and dosage intervals that are suitable for neonates during 381 
and after hypothermia. 382 
  3.2.1 Phenobarbital and hypothermia 383 
Positive synergism of first-line AED phenobarbital and hypothermia was observed in a rodent 384 
model of HIE, with both early and late assessment of neuropathology and sensorimotor 385 
performance demonstrating improvements [138]. However, current evidence suggests that this 386 
combination has not translated to a reduced risk of death or brain damage in neonates [139, 387 
140]. Seizures were detected using aEEG, and a 66% reduction in seizures was demonstrated 388 
for neonates treated with hypothermia and with plasma concentrations of phenobarbital above 389 
20mg/L [140].  390 
The pharmacokinetics of phenobarbital were examined in hypothermic critically-ill neonates 391 
[100, 101]. It was found that minimum, maximum and average plasma concentrations were all 392 
larger in cooled neonates versus normothermia [100]. However, Vd and clearance remained 393 
unchanged [101]. It was concluded the alterations in pharmacokinetics of phenobarbital during 394 
hypothermia in neonates were not clinically significant, and that a total maximum dose of 395 
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40mg/kg can be safely administered in hypothermia prior to initiation of second-line AED 396 
[140]. In contrast, metabolism of phenobarbital via CYP2C19 was significantly reduced when 397 
it was administered to critically injured children who were cooled under more severe 398 
hypothermic conditions to 30-31ºC [135, 141]. Therapeutic drug monitoring of phenobarbital 399 
allows for tight control of AED concentrations, which may be particularly important during 400 
hypothermia.  401 
  3.2.2 Lidocaine and hypothermia 402 
Lidocaine was administered as a third-line anticonvulsant to neonates undergoing hypothermia 403 
treatment for asphyxia-induced seizures with aEEG monitoring. An impressive 91% of these 404 
patients responded to lidocaine [134]. This is a similar response rate to that observed in 405 
normothermic babies [42].  406 
The pharmacokinetics of lidocaine are altered by hypothermia. Clearance of lidocaine is 407 
reduced by 24% as hepatic blood flow is reduced during hypothermia [134]. Despite these 408 
changes, no cardiotoxicity was observed in hypothermic neonates when an altered dosing 409 
regimen, equating to 70% of the total lidocaine dose given to normothermic neonates, was 410 
administered [134].  411 
  3.2.3 Topiramate and hypothermia 412 
Animal studies suggested that the combination of topiramate and hypothermia improved motor 413 
and brain tissue damage in a model of HIE, where neither drug alone conferred any 414 
neuroprotection [142]. In neonates, there were no statistically significant changes in survival 415 
rate or brain damage observed when topiramate was given in combination with hypothermia 416 
when compared to hypothermia alone [97]. A randomised-controlled trial of topiramate and 417 
hypothermia in combination is underway, which will examine efficacy of seizure control with 418 
this treatment strategy (NCT01765218) [38, 81]. 419 
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The pharmacokinetic profile of topiramate is altered when administered during hypothermia 420 
treatment: maximum, minimum and average concentrations, t1/2 and area under the 421 
concentration-time curve are significantly higher in hypothermia [96]. However, these 422 
pharmacokinetic variations are not clinically significant, and the majority of neonates are 423 
observed to have topiramate concentrations within the safe, effective concentration range [96].  424 
  3.2.4 Midazolam and hypothermia 425 
The efficacy of midazolam as a second-line AED in seizing neonates undergoing hypothermia 426 
treatment is modest, achieving seizure control in only 23% of neonates, confirmed using aEEG 427 
monitoring [75].  428 
The pharmacokinetic profile of midazolam in neonates were not significantly changed by 429 
hypothermia [75, 143]. However, the incidence of midazolam-induced hypotension increased 430 
in neonates undergoing therapeutic hypothermia [75]. Midazolam levels in the serum of 431 
asphyxiated infants (both normothermic and hypothermic) were found to be highly variable 432 
and unpredictable, due to renal/hepatic impairment caused by the initial injury [143]. 433 
Furthermore, it is worth noting that the combination of midazolam and hypothermia in adults 434 
with disorders of the CNS gave rise to significant decreases in clearance and increases in Vd of 435 
midazolam compared to midazolam treatment alone [144]. 436 
  3.2.5 Bumetanide and hypothermia 437 
Bumetanide pharmacokinetics including clearance and Vd were calculated in a neonatal 438 
population [64]. These patients were also receiving hypothermia treatment and phenobarbital. 439 
Clearance values appear to generally be in agreement with values previously reported in a 440 
neonatal population [145, 146]. The combination of phenobarbital, bumetanide and 441 
hypothermia in a neonatal population with HIE-induced seizures was not effective, as none of 442 
24 
 
the neonates achieved the requisite 80% seizure reduction without the need for rescue AEDs 443 
[64, 86]. 444 
  3.2.6 Phenytoin and hypothermia 445 
There are no data from neonates with seizures on the efficacy or safety of phenytoin and 446 
hypothermia together. However, there are reports from trials on the use of phenytoin and 447 
hypothermia in older children aged 2-16 years, as well as adult patients, for the treatment of 448 
traumatic brain injury [147, 148]. In these populations, decreases in metabolism by CYP2C9 449 
and CYP2C19 resulted in reduced clearance compared to values obtained after rewarming 450 
[135, 147, 148]. In children, it was also found that increased phenytoin levels are present both 451 
during and after rewarming which increased the risk of drug toxicity even after hypothermia 452 
had finished [147]. Moreover, a case report has described an additive bradycardic effect of 453 
therapeutic hypothermia and phenytoin [149]. Hypothermia in this case occurred during 454 
surgery and was not controlled. The authors hypothesise that the cardiac depressant effects of 455 
both treatments acted synergistically and that extreme caution should be exercised when co-456 
administration is necessary [149].  457 
  458 
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4. Knowledge gaps 459 
There is an urgent need for more randomised controlled trials in neonates to validate a treatment 460 
algorithm for seizures, especially when used in combination with hypothermia. Due to a lack 461 
of evidence from clinical studies, seizure treatments consist of older generation drugs that have 462 
more side-effects than newer drugs [3]. In general, efficacy rates of treatments are 463 
underwhelming (Table 1). Furthermore, there is a need to observe long-term 464 
neurodevelopmental outcomes following each of the proposed treatments, and to define the 465 
optimal length of time to continue with AED therapy given the concern regarding their effect 466 
on long-term brain development [16, 150]. 467 
There is a paucity of data on the pharmacokinetics and efficacy of many AEDs used in 468 
neonates, including levetiracetam, lidocaine and topiramate [151]. There are also major gaps 469 
in our knowledge about the efficacy and safety of most anticonvulsant drugs, particularly in 470 
preterm neonates. 471 
 In HIE it is imperative that the pharmacokinetics of AEDs during both active therapeutic 472 
hypothermia and the rewarming phase in neonates with seizures are elucidated, particularly 473 
with regards to phenytoin, a popular second-line AED [135]. Furthermore, drug-drug 474 
interactions are significantly under-investigated, especially co-administration of AEDs with 475 
novel neuro-protective drugs such as xenon, allopurinol, melatonin and erythropoietin.  476 
Multichannel EEG is essential to accurately measure the efficacy of AEDs [24]. The optimal 477 
algorithm for detecting seizures remains to be developed, to enhance bedside recognition of 478 
seizures by non-EEG experts.  479 
In the last decade there has been an increased interest in developing safe and effective drugs 480 
for neonates. The European Commission through the FP7 Framework promoted research on 481 
the safe and effective use of medicine in children by specifically supporting applications for 482 
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the neonatal age group [152]. More recently, the International Neonatal Consortium was 483 
launched in May 2015. This is a consortium of stakeholders focused on the development of 484 
effective medicines for neonates, including the Food and Drug Administration (FDA), 485 
European Medicines Agency (EMA), the pharmaceutical industry, academia, patient research 486 
groups, and family advocates. The consortium aims to align priorities and initiate 487 
collaborations to accelerate the development of safe and effective treatments for neonates. One 488 
of the first topics that this consortium has prioritised for further development is the treatment 489 
of neonatal seizures.  490 
5. Conclusion 491 
The treatment of neonatal seizures remains sub-optimal. Treatment algorithms are based on 492 
minimal trial data on older generation drugs. Phenobarbital remains the first-line antiepileptic 493 
of choice, despite suboptimal efficacy and altered underlying pharmacodynamics in the 494 
immature brain. However, there is no consensus on a replacement first-line drug or even on the 495 
most efficacious and suitable second-line AED. A lack of randomised controlled trials to guide 496 
treatment regimens in neonatal seizures is halting progress in the field. There are a multitude 497 
of drug-drug and drug-hypothermia interactions that remain to be elucidated, including the 498 
efficacy/safety of antiepileptic polypharmacy in neonates. These knowledge gaps have been 499 
identified and urgently need to be bridged by designing and conducting high quality clinical 500 
trials in neonates. Until the pharmacokinetic/pharmacodynamic profiles of antiepileptic 501 
medications in hypothermia are sufficiently investigated, therapeutic drug monitoring of serum 502 
antiepileptic levels is encouraged. The efficacy of antiepileptic treatment protocols should 503 
always be measured using cEEG monitoring.  504 
 505 
 506 
 507 
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Fig. 1 Mode of action of neonatal AEDs 943 
Many drugs act by reducing excitatory neurotransmission (glutamatergic synapse). Phenytoin, 944 
lidocaine and topiramate prevent depolarisation by inhibiting voltage-gated sodium channels 945 
[50, 51]. Levetiracetam prevents calcium influx through N-type calcium channels which in turn 946 
reduces exocytosis and reduces the release of glutamate from intracellular vesicles by 947 
modulating synaptic vesicle protein 2A (SV2A) [51, 52]. On the postsynaptic terminal, 948 
phenobarbital and topiramate reduce excitatory neurotransmission via the AMPA/kainate 949 
glutamate receptor [51, 53]. Anticonvulsants including phenobarbital, benzodiazepines and 950 
topiramate work by enhancing inhibitory neurotransmission via the GABAA receptor 951 
(GABAergic synapse) [51]. Bumetanide can alter the action of GABAergic agents by 952 
preventing intracellular accumulation of chloride through NKCC1 [17].  953 
(AMPA = α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; NMDA = N-methyl-D-954 
aspartate; GABA = γ-amino butyric acid; GAD = glutamic acid decarboxylase; SV2A = 955 
synaptic vesicle protein 2A) 956 
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 958 
